Entries by

Building in vivo potency and duration of action and into a novel inhaled ENaC blocker, ETD001, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

Inhaled drugs are typically cleared very rapidly from the airway mucosa. Inhaled amiloride, accelerated mucociliary clearance in clinical studies, but with a half-life in the airway mucosa of <30 min, it was a short acting effect which did not translate into clinical efficacy. To achieve a long duration of action in the clinic with novel […]

Identifying pathways regulating goblet cell metaplasia: phenotypic screening with bronchospheres, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

It is widely accepted that the composition of mucus in the CF airway, and in particular the hydration status, significantly affects its clearance and thereby the potential for form plugs, restrict airflow and create a nidus for chronic microbial colonisation. A variety of largely ion channel-based strategies are being employed to promote mucosal hydration e.g. […]

Enterprise Therapeutics receives funding from Cystic Fibrosis Trust

Award will support research into the use of bronchosphere technology as innovative treatment Brighton, UK – 05 April, 2017: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for […]

The discovery of novel TMEM16A potentiator compounds, presented at the Gordon research Conference, “Mucus & Mucociliary interactions”, Galveston, USA, February 2017

It is widely accepted that the composition of mucus in the CF airway, and in particular the hydration status, significantly affects its clearance and thereby the potential for form plugs, restrict airflow and create a nidus for chronic microbial colonisation. A variety of largely ion channel-based strategies are being employed to promote mucosal hydration e.g. […]

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising

Brighton, UK – 10th November, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed a £4 million ($5 million USD) financing. The funding was led by existing investors Epidarex Capital and Imperial Innovations and will […]

Enterprise Therapeutics appoints Dr John Ford as CEO

Brighton, UK – October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has appointed Dr John Ford as CEO with immediate effect. Enterprise Therapeutics is developing novel muco-regulatory therapies for patients suffering with Chronic […]

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

The TLR5-agonist flagellin (FLG) is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. The proinflammatory activity of bacterial FLG has been well documented in leukocytes although the effects on airway epithelial function are less clear. More information

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium (Caputo et al 2008; Schroeder et al 2008; Yang et al 2008). It is now clinically established that promoting anion secretion in the airway leads to enhanced mucus clearance and reduced exacerbation frequency in […]